Smallpox

Smallpox

Biodefense Headlines – 29 September 2024

News Scan September 29, 2024

This edition includes a Marburg virus outbreak in Rwanda, the trajectory of the global H5N1 panzootic, and the public health emergency response to states hit by Hurricane Helene. FEATURED Rwanda Confirms Cases of Marburg Virus Disease, Steps Up Preventive Measures…

PharmAthene Receives 5M Initial Payment from SIGA

Phase 1 Trial Begins for IV Version of Smallpox Drug

SIGA Gets Greenlight on Smallpox Drug Phase 3 Trial

U.S. Government Places 133M Smallpox Vaccine Order

U.S. Moves Forward with Stockpiling of Second Smallpox Antiviral

Smallpox Vaccine Performs Well in Two Pivotal Studies

Misconceptions About Smallpox’s Role in Native Depopulation

Smallpox Vaccine Virus Helps UNL Scientist Understand Immunity

PharmAthene Awarded $195M+ in SIGA Smallpox Lawsuit

Chimerix Speeding Up Brincidofovir Trials for Ebola

Chimerix EIND Authorized for Patients with Ebola Virus

Emergent BioSolutions Awarded 19M for Smallpox Drug

Transcript of CDC Press Conference on Biosafety Incidents

Smallpox Vials Discovered in NIH Storage Room

Scientists Again Call for Delay in Destruction of Last Stocks of Smallpox

Children Conceived During Epidemic Have More Lifetime Resistance

BARDA Moves Forward on Freeze-Dried Smallpox Vaccine

Bavarian Nordic to Develop Biodefense Vaccine

Emergent Expands Biodefense Holdings with Acquisition of Cangene

Bavarian Nordic Completes Smallpox Vaccine Delivery to SNS

Biodefense Headlines – 29 September 2024